Terms: = Ovarian cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
11 results:
1. FDA Approval Summary: Selpercatinib for the treatment of Advanced ret Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract] [Full Text] [Related]
2. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract] [Full Text] [Related]
3. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
4. Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations.
Poli R; Scatolini M; Grosso E; Maletta F; Gallo M; Liscia D; Nelva A; Cesario F; Forte G; Metovic J; Volante M; Arvat E; Papotti M
Endocrine; 2021 Jan; 71(1):216-224. PubMed ID: 32743766
[TBL] [Abstract] [Full Text] [Related]
5. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract] [Full Text] [Related]
6. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Matulonis UA; Sill MW; Makker V; Mutch DG; Carlson JW; Darus CJ; Mannel RS; Bender DP; Crane EK; Aghajanian C
Gynecol Oncol; 2019 Mar; 152(3):548-553. PubMed ID: 30587441
[TBL] [Abstract] [Full Text] [Related]
7. Cabozantinib: a MET, ret, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract] [Full Text] [Related]
8. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
[TBL] [Abstract] [Full Text] [Related]
9. Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Harter P; Sehouli J; Kimmig R; Rau J; Hilpert F; Kurzeder C; Elser G; du Bois A
Invest New Drugs; 2013 Dec; 31(6):1499-504. PubMed ID: 24005613
[TBL] [Abstract] [Full Text] [Related]
10. Expression of ret finger protein predicts chemoresistance in epithelial ovarian cancer.
Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
[TBL] [Abstract] [Full Text] [Related]
11. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract] [Full Text] [Related]